Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries)
43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file · Peer-reviewed
What this source contributed
Records in this release that cite this source. A record can cite several sources.
Results
Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.
Claims
Statements this source supports, each with where in the source it was checked.
- Evidence summary: plasma ctDNA fragmentomics workflows: Summary Eight sources compare plasma cfDNA fragmentomic workflows on retrospective case-control cohorts. None is a prospective screening study and none measures clinical benefit. Cristiano et al. 2019, the DELFI developers, report 73% sensitivity (152 of 208 cancers) at a reported 98% specificity for DELFI in repeated cross-validation against 215 healthy individuals. Hou et al. 2024 re-implemented ten published fragmentation patterns and DELFI with one support vector machine each on the same cohort. They are independent of every pattern except IFS, which their corresponding author developed. In 10 x 10-fold cross-validation, pan-cancer AUC within open chromatin regions ranged from 0.8741 (fragment length) to 0.9736 (5' end motif), and their DELFI re-implementation reached 0.9575. Rankings changed on independent cohorts. On 46 lung cancers and 385 healthy individuals, with a model trained on 12 lung cancers, the end-motif model fell to AUC 0.5355 and sensitivity 0.0652 at 95% specificity, while fragment size distribution reached 0.9386 and 0.7174. Hou et al.'s supplementary pan-cancer and liver cancer sensitivities conflict with other tables of the same file and are not shown. Wang et al. 2026, the UNITE developers, stratified cancers by ichorCNA tumour fraction in pooled public and new 0.1x data that include samples of the DELFI and Jiang et al. cohorts used above. For cancers with an estimated tumour fraction of 3% or less, cross-validated AUC was 0.878 for all five features combined, 0.873 for fragment length, 0.857 for the SD of length counts, 0.736 for copy number, 0.715 for the C/T end-motif ratio and 0.651 for the short/long ratio, against 0.603 for a classifier using the ichorCNA tumour fraction alone, which detected 0.058 of these cancers at 95% specificity. For cancers with an estimated fraction above 3% and up to 10%, the ichorCNA classifier reached 0.983, above the combined model (0.962) and copy number alone (0.926). The extracted UNITE tables give sensitivity at a fixed specificity only for the ichorCNA comparator; the fragmentomic models' values are in a sheet not yet extracted. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, scored fragment length and fragment endpoint classifiers from 30x cfDNA whole-genome sequencing on the same CCGA substudy 1 participants as their methylation, copy-number and variant classifiers, at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers the fragment length classifier detected 29% (95% CI 25% to 34%) and the fragment endpoint classifier 18% (15% to 22%), against 34% for whole-genome methylation analysed double-blinded; both fragment classifiers were developed after the validation set had been unblinded, so these are not blinded validation results, and no tumour-fraction-stratified sensitivity is printed. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, computed fragmentomic features from cfMeDIP-seq reads, which are enriched for methylated fragments rather than drawn from whole-genome sequencing, and report means over 10 fold models. On an independent paired-end validation set, a fragment-ratio classifier reached AUC 0.848 and detected 0.533 of cancers at 99% specificity, and fragment ratios combined with methylation reached 0.954 and 0.766. The validation set has 17 healthy controls, so its 99% specificity allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in its sensitivities. Three of the five classifiers that include end motifs scored below AUC 0.5 there, which the authors attribute to healthy controls processed with a different laboratory protocol, so validation results for all five are not shown. Helzer et al. 2025 (Nature Communications) compared twelve fragmentomic metrics adapted to targeted exon panels, including the authors' own fragment-size entropy metrics, their combination and Griffin, with one classifier and shared folds, on plasma from patients with metastatic cancer. The healthy-versus-cancer one-vs-rest AUROC ranged from 0.835 (open-chromatin entropy) to 0.989 (first-exon depth) in a UW cohort of 404 cancers and 27 healthy donors, with Griffin at 0.944, and from 0.951 to 1.000 in public GRAIL panel data from 151 cancers and 47 healthy donors. In a developer comparison on 0.1x whole-genome sequencing (Cell Reports Medicine 2026), a fragment-level language model (Fragmentia-AI) reached AUC 0.9561 on a held-out set of unstated size, against 0.9209 to 0.935 for the developers' re-implementation of DELFI features and 0.881 to 0.8863 for Griffin features under three classifiers. The same company's whole-genome model (Molecular Biomedicine 2026), on an independent test cohort of 2,952 cancers and 3,044 non-cancer controls, reached AUC 0.910 for cancers with an ichorCNA tumour fraction below 3% and detected 0.46 of them at a cutoff set to 98% specificity in training (observed test specificity 0.97); among those low-fraction cancers it detected 0.391 at stage I/II (637 of 1,628) and 0.708 at stage III/IV (345 of 487). Its tumour-fraction strata are ichorCNA estimates, no comparator was run on its cohorts, and its training cohort has the same number of non-cancer controls (1,245) as the Cell Reports Medicine cohort, so the two studies may share samples. Three of these four studies report on their authors' own method, and in the fourth the authors' own entropy metrics are among those compared. Cohorts, feature implementations, classifiers and validation designs differ, so no value is comparable across sources. (amp-20261007-ctdna-fragmentomics-source: result amp-20261007-ctdna-fragmentomics-result; ctdnafrag-20261009-source-hou2024: Table 1, P24 and P44; ctdnafrag-20261009-source-hou2024-supporting-information: Table S3; ctdnafrag-20261009-source-wang2026-data-file-s2: STATS_xgb_x1-x6 and STATS_lr; ctdnafrag-20261009-source-wang2026: Results and Methods; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4c and Fig.4d; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Tables S1 and S2, 'Normal' columns; ctdnalit-20261011-helzer2025-source-article: Results P5-P8; ctdnalit-20261011-fragmentia2026-source-document-s1: Table S5; ctdnalit-20261011-fragmentia2026-source-article: Results P39-P44; ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Tables S1 and S4)
- Evidence summary: plasma ctDNA methylation detection workflows: Summary Six bounded sources compare cfDNA methylation methods. None is a prospective screening study and none measures clinical benefit. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, compared prototype cfDNA classifiers on the same CCGA substudy 1 participants at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers, analysed double-blinded, the whole-genome bisulfite methylation classifier detected 34% of cancers (95% CI 30% to 39%; 158 of 464), against 33% for variants with white-blood-cell correction, 30% for copy number with that correction, 27% for copy number, 16% for uncorrected variants and 2.6% for clinical risk factors alone; only the gap to the corrected variant classifier was not marked as significant. Among 127 validation cancers detected by all three representative classifiers, a methylation origin classifier developed after unblinding assigned the correct tissue for 75% (95 of 127), against 41% for copy number and 35% for corrected variants, with 'other' counted as correct for six cancer types. These are case-control results from the assay developer, not screening performance. Sun et al. 2024 (Genome Biology), an independent benchmark whose authors did not develop the tools, deconvolved real plasma with five methods and reported the ROC-AUC of a random forest trained on the estimated cell-type fractions; the paper does not state how the random forest was validated, so the AUCs may be in-sample. For 24 liver cancer patients and 32 healthy individuals (WGBS), AUCs were 0.96 (CelFEER), 0.93 (CelFiE), 0.91 (MethAtlas), 0.77 (cfNOMe) and 0.72 (UXM). On cfMethyl-Seq plasma (30 to 67 patients per cancer type, each against the same 193 healthy individuals), AUCs ranged from 0.72 (UXM, lung squamous cell carcinoma) to 0.93 (CelFiE, gastric cancer), and no method was highest for every cancer type. Giuili et al. 2025, a bioRxiv preprint not yet peer reviewed, ran ten reference-based tools inside the authors' DecoNFlow pipeline on in silico mixtures of tumour tissue or cell-line reads in healthy plasma reads. CelFiE had the lowest overall median tumour-fraction limit of detection in each dataset: 0.0070 (WGBS-TT), 0.0100 (RRBS-TT) and 0.0010 (RRBS-CL). CIBERSORT and EpiDISH had overall medians of 0.1000 to 0.2500 on WGBS-TT and RRBS-TT. For five tools the RRBS-CL values disagree between the supplementary table and Figure 4A and are not shown. Nguyen et al. 2023 (eLife), by the developers of the SPOT-MAS assay at Gene Solutions, compared three tissue-of-origin classifiers on combined methylation, fragment-length, copy-number and end-motif features from cancer patients only. In the validation cohort of 239 patients, overall accuracy was 0.53 (random forest), 0.69 (deep neural network) and 0.69 (graph convolutional network); the graph network was trained with the validation samples in its graph. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, compared a cfMeDIP-seq methylation classifier with fragmentomic features of the same reads and their combinations, reporting means over 10 fold models. In cross-validation on 356 cancers and 64 healthy donors, methylation alone reached AUC 0.986 and detected 0.949 of cancers at 99% specificity; on an independent validation set its sensitivity at 99% specificity was 0.633, against 0.766 for methylation combined with fragment ratios. These sensitivities are read on few healthy controls (six or seven per cross-validation fold and 17 in the validation set), so 99% specificity there allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in the validation sensitivities. The Source Data give the methylation-only validation AUC as 0.694 and the text as 0.674, so that value is not shown. Xu and Feng 2026, a medRxiv preprint not yet peer reviewed, by authors who did not develop CpGPT, fine-tuned the CpGPT methylation foundation model on public targeted bisulfite cfDNA data from 254 gastrointestinal cancers and 46 non-cancer controls and built four classical classifiers themselves. On three train/validation/test splits with test partitions of about 30 samples, mean test AUROC was 0.9904 for CpGPT against 0.9573 (SVM), 0.9420 (elastic net), 0.8460 (gradient boosting) and 0.8408 (random forest); the candidate CpGs were selected using all 300 samples, including the test partitions. Neither study reports performance in a screening population. Tissue-of-origin evidence here comes from two developer studies, one methylation-only classifier scored on already detected cancers and one multimodal workflow, and neither classifies people without cancer. (ctdnameth-20261009-source-sun2024-additional-file-1: Table S7 I4:M4, M8, J9; ctdnameth-20261009-source-sun2024: Methods P30; ctdnameth-20261009-source-giuili2025-supp-table-3: sheet B B3:D4, B7:C7; ctdnameth-20261009-source-nguyen2023-supp-file-1: Table S9 B19:E19; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4a-Fig.4d; ctdnalit-20261011-cpgpt2026-source-preprint: Table 3; Methods; Results)
- Relevance of ctdnalit-20261011-zeng2026-protocol-pe-primary-cv to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation (ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h)
- Relevance of ctdnalit-20261011-zeng2026-protocol-pe-primary-cv to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?": Assessed by Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation (ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h)
- Relevance of ctdnalit-20261011-zeng2026-protocol-pe-validation to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Zeng et al. 2026 independent PE validation dataset: cancer vs healthy (ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h)
- Relevance of ctdnalit-20261011-zeng2026-protocol-pe-validation to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?": Assessed by Zeng et al. 2026 independent PE validation dataset: cancer vs healthy (ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h)
- Relevance of ctdnalit-20261011-zeng2026-protocol-se-primary-cv to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?": Assessed by Zeng et al. 2026 primary SE dataset: cancer vs healthy, nested cross-validation (ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h)
- Relevance of ctdnalit-20261011-zeng2026-protocol-se-validation to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?": Assessed by Zeng et al. 2026 SE 10% hold-out set: cancer vs healthy (ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h)
Models, benchmarks and other records
Methods (1)
Configurations (10)
- Zeng et al. 2026 classifier: Combined All Features (1%)
- Zeng et al. 2026 classifier: Combined All Features (5%)
- Zeng et al. 2026 classifier: Combined Motif + Methylation (1%)
- Zeng et al. 2026 classifier: Combined Motif + Methylation + Ratios (1%)
- Zeng et al. 2026 classifier: Combined Ratios + Methylation (1%)
- Zeng et al. 2026 classifier: End Motifs
- Zeng et al. 2026 classifier: Fragment Ratio
- Zeng et al. 2026 classifier: Insert Size
- Zeng et al. 2026 classifier: Methylation
- Zeng et al. 2026 classifier: Nucleosome Peak
Protocols (4)
Datasets (4)
Evaluations (26)
- Combined All Features (1%) on pe primary cv (Zeng et al. 2026)
- Combined All Features (1%) on pe validation (Zeng et al. 2026)
- Combined All Features (5%) on pe primary cv (Zeng et al. 2026)
- Combined All Features (5%) on pe validation (Zeng et al. 2026)
- Combined Motif + Methylation (1%) on pe primary cv (Zeng et al. 2026)
- Combined Motif + Methylation (1%) on pe validation (Zeng et al. 2026)
- Combined Motif + Methylation (1%) on se primary cv (Zeng et al. 2026)
- Combined Motif + Methylation (1%) on se validation (Zeng et al. 2026)
- Combined Motif + Methylation + Ratios (1%) on pe primary cv (Zeng et al. 2026)
- Combined Motif + Methylation + Ratios (1%) on pe validation (Zeng et al. 2026)
- Combined Ratios + Methylation (1%) on pe primary cv (Zeng et al. 2026)
- Combined Ratios + Methylation (1%) on pe validation (Zeng et al. 2026)
- End Motifs on pe primary cv (Zeng et al. 2026)
- End Motifs on pe validation (Zeng et al. 2026)
- End Motifs on se primary cv (Zeng et al. 2026)
- End Motifs on se validation (Zeng et al. 2026)
- Fragment Ratio on pe primary cv (Zeng et al. 2026)
- Fragment Ratio on pe validation (Zeng et al. 2026)
- Insert Size on pe primary cv (Zeng et al. 2026)
- Insert Size on pe validation (Zeng et al. 2026)
- Methylation on pe primary cv (Zeng et al. 2026)
- Methylation on pe validation (Zeng et al. 2026)
- Methylation on se primary cv (Zeng et al. 2026)
- Methylation on se validation (Zeng et al. 2026)
- Nucleosome Peak on pe primary cv (Zeng et al. 2026)
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
20 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Archive note Not archived in the batch: CC BY-NC-ND 4.0; the 17,627-byte file is pinned by hash. Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Artifact SHA-256 fae751686bbe1a15c5e1e2312b8679afd235a97b305b56f925744788ab0163b4 Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Artifact url https://static-content.springer.com/esm/art%3A10.1038%2Fs43018-026-01116-3/MediaObjects/43018_2026_1116_MOESM6_ESM.xlsx Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Doi 10.1038/s43018-026-01116-3 Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Licence CC-BY-NC-ND-4.0 Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Media type application/vnd.openxmlformats-officedocument.spreadsheetml.sheet Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Publication status peer_reviewed Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Retrieval note The same bytes are served inside the Europe PMC supplementaryFiles bundle for PMC12948677 (checked 2026-10-11T21:40:45Z). Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Retrieved at 2026-10-11T21:41:25Z Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Source location Sheets Fig.4a to Fig.4h; per-result locators on each result Source metadata | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) No field-specific location recorded Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
Supplementary Source Data workbook retrieved and hashed for the 2026-10-11 plasma ctDNA literature pass.
Technical metadata and extraction receipts
Stable ID: ctdnalit-20261011-zeng2026-source-source-data-fig4
- areas
- dna-genomes
- contexts
- clinical_research
- url
- https://doi.org/10.1038/s43018-026-01116-3
- artifact url
- https://static-content.springer.com/esm/art%3A10.1038%2Fs43018-026-01116-3/MediaObjects/43018_2026_1116_MOESM6_ESM.xlsx
- version
- 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file
- retrieved at
- 2026-10-11T21:41:25Z
- artifact sha256
- fae751686bbe1a15c5e1e2312b8679afd235a97b305b56f925744788ab0163b4
- doi
- 10.1038/s43018-026-01116-3
- publication status
- peer_reviewed
- licence
- CC-BY-NC-ND-4.0
- media type
- application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
- source locator
- Sheets Fig.4a to Fig.4h; per-result locators on each result
- retrieval note
- The same bytes are served inside the Europe PMC supplementaryFiles bundle for PMC12948677 (checked 2026-10-11T21:40:45Z).
- archive note
- Not archived in the batch: CC BY-NC-ND 4.0; the 17,627-byte file is pinned by hash.